rs727504307
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 4P and 1B. PM1PM2BP4
The ENST00000307340.8(USH2A):c.10826G>T(p.Ser3609Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000192 in 1,461,884 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S3609T) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000307340.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
USH2A | NM_206933.4 | c.10826G>T | p.Ser3609Ile | missense_variant | 55/72 | ENST00000307340.8 | NP_996816.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.10826G>T | p.Ser3609Ile | missense_variant | 55/72 | 1 | NM_206933.4 | ENSP00000305941 | P1 | |
USH2A | ENST00000674083.1 | c.10826G>T | p.Ser3609Ile | missense_variant | 55/73 | ENSP00000501296 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000915 AC: 23AN: 251356Hom.: 1 AF XY: 0.0000883 AC XY: 12AN XY: 135836
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1461884Hom.: 1 Cov.: 32 AF XY: 0.0000193 AC XY: 14AN XY: 727242
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 14, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 27, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 13, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 03, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Ser3609Ile va riant in USH2A has been identified by our laboratory in 1 Latino individual with hearing loss and in 6/1154 Latino chromosomes by the Exome Aggregation Consorti um (ExAC, http://exac.broadinstitute.org; dbSNP rs727504307). The Serine (Ser) a t position 3609 is not conserved in mammals or evolutionary distant species, and 2 mammals (horse and platypus) carry an isoleucine (Ile) at this position, rais ing the possibility that this change may be tolerated. Additional computational prediction tools suggest that the p.Ser3609Ile variant may not impact the protei n, though this information is not predictive enough to rule out pathogenicity. I n summary, while the clinical significance of the p.Ser3609Ile variant is uncert ain, these data suggest that it is more likely to be benign. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 30, 2024 | The c.10826G>T (p.S3609I) alteration is located in exon 55 (coding exon 54) of the USH2A gene. This alteration results from a G to T substitution at nucleotide position 10826, causing the serine (S) at amino acid position 3609 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Usher syndrome type 2A Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at